SANGUINATE®, currently in clinical development, is an investigational bio-pharmaceutical product that facilitates the transfer of oxygen to oxygen-deprived cells and tissues. Prolong’s current focus is using this unique oxygen-delivery system to treat the vaso-occlusive crisis of sickle cell disease (SCD) and other disorders caused by anemia or hypoxia/ischemia.
SANGUINATE® is in clinical development to treat the vaso-occlusive crisis of SCD, and it has an Orphan Drug Designation from the U.S. FDA for the treatment of SCD comorbidities. Many of the comorbidities of SCD are caused by a spiraling cycle of sickling, hemolysis, and blood vessel inflammation. These comorbidities include vaso-occlusive (pain) crisis, acute chest syndrome, leg ulcers, and pediatric and adult stroke.
Phase II studies in patients with vaso-occlusive crisis of SCD have completed enrollment in the fourth quarter of 2017 and the data gathered from these trials is under analysis.